Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Scripps Research Institute
With
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
This is a double-blind, 3-cell, outpatient human laboratory study to determine the degree to which acamprosate and naltrexone will suppress subjective and physiological responsivity to alcohol cues relative to placebo in early abstinence.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females ≥ 18 and ≤ 55 years of age
Meets Diagnostic and Statistical Manual-Fourth Edition (DSM-IV) criteria for current alcohol dependence
Does not desire treatment
Alcohol free, as verified by breath alcohol concentration, with a Clinical Institute Withdrawal Assessment (CIWA) ≤ 8, at the time of testing, with no evidence of drinking for at least 3 days but no more than 7 days prior to the cue reactivity session
Able to complete and understand questionnaires and study procedures in English
Verbal I.Q. estimate ≥ 85
Signed informed consent
You may not be if
Currently meets DSM-IV criteria for dependence on substances other than alcohol or nicotine
Significant medical disorders that will increase potential risk or interfere with study participation
Sexually active women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control
Meets DSM-IV criteria for a major Axis I disorder, including depression or anxiety disorders
Treatment within the month prior to screening with investigational medications or those which may influence drinking outcome, e.g., disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral), antidepressants or other psychotropic agents
Chronic treatment with any narcotic-containing medications during the previous month or evidence of current opiate use
Liver function tests more than three times normal or elevated bilirubin
No fixed domicile and/or no availability by telephone or beeper
Current involvement in or plans for treatment prior to study completion
Patients who have a history of adverse drug reactions to the study drugs or their ingredients
Failure to take double-blind medication as prescribed
Inability to understand or comply with the provisions of the protocol or consent form
